Enzyme target to latch on to

Abstract

Insulin-degrading enzyme is implicated in diabetes and Alzheimer's disease, but few molecular tools exist that can probe its function. A study now reveals its unusual structure and may lead to an expanded toolbox. Insulin-degrading enzyme (IDE) is involved in the clearance of insulin and amyloid β. This is necessary to maintain proper blood sugar levels and to prevent accumulation of amyloid β in the brain. The crystal structure of IDE in complex with four substrates has now been determined, revealing the molecular basis for substrate recognition. This should aid the design of IDE-based drugs for Alzheimer's disease and type II diabetes.